Adam Asch

机构：University of Oklahoma Medical Center, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center

发表论文 51 篇 · 总被引 909 次 · h-index 10

代表论文

• T-cell antigen receptor Vβ subsets are not preferentially deleted in AIDS (1993 · AIDS · 被引 61)
• AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results (2021 · Clinical Lymphoma Myeloma & Leukemia · 被引 52)
• Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML (2023 · Journal of Clinical Oncology · 被引 49)
• THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS (2019 · Hematological Oncology · 被引 30)
• Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial (2022 · The Lancet Oncology · 被引 27)
• Human immunodeficiency virus 1 reservoir in CD4+ T cells is restricted to certain V beta subsets. (1995 · Proceedings of the National Academy of Sciences · 被引 21)